A new-generation clinical trial for glioblastoma multiforme (GBM) — the deadliest form of brain cancer – will begin enrolling patients by mid-year 2016. The trial is designed to identify effective treatments faster for this aggressive form of brain cancer which kills half of all patients diagnosed within one year. Five years after diagnosis, the survival rate is less than 2 percent.
The international trial is adaptive, meaning...
A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated...
An MD Anderson study may explain why chemotherapy drugs such as gemcitabine are ineffective against pancreatic cancer in some patients. The...
A team led by researchers at MD Anderson Cancer Center reports a crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system. The study was published in the Journal of the National Cancer Institute.
“Identifying this role for tumor-suppressing p53 provides both a potential biomarker for response to important new cancer immunotherapy...
A cadre of elite surgeons is making a mark as pioneering researchers at MD Anderson. In the operating room, they’re not just excising tumors...
Cetuximab, marketed as Erbitux®å, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients...
Diets high in meats cooked by high-temperature techniques such as barbecuing and pan-frying, which produce carcinogenic compounds, may lead...
Leveraging recent advances in the biology of extracellular vesicles and their role in intercellular communication, Codiak BioSciences, Inc...
MD Anderson Cancer Center was awarded more than $22 million in research grants in November from the Cancer Prevention and Research Institute...
Distinguished contributions to understanding p53 tumor suppression in stem cells and breakthrough advances in treating breast cancer have...